Compare Amplitude Inc (AMPL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Sanofi SA — how do they compare? Amplitude Inc trades at $9.21 (market cap $1.22B), while Sanofi SA trades at $43.71 (market cap $103.90B). The key difference: Sanofi SA is far larger — about 85.2× Amplitude Inc's market cap, and Sanofi SA pays a 5.56% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.
| AMPL | SNY | |
|---|---|---|
Market Cap | $1.22B | $103.90B |
Sector | Technology | Health |
52-Week High | $13.04 | $52.34 |
52-Week Low | $5.61 | $41.33 |
Enterprise Value | $1.05B | $120.39B |
Dividend Yield | — | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $9.18, down 2.13% over the past day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, reaching $343.21M in 2025, yet the company remains unprofitable with a net income margin of -25.11%. Analyst consensus is bullish with a $9.25 price target, though recent news includes multiple law firm fraud investigations and a Bank of America downgrade citing profitability concerns.
The outlook hinges on AMPL's ability to translate robust revenue growth into profitability amid competitive pressures. Investment opportunity lies in potential margin expansion and market share gains, but risks include ongoing legal scrutiny, execution challenges, and persistent negative cash flows. The stock's near-term direction will likely be driven by upcoming earnings results and clarity on the fraud allegations.
SNY trades at $43.50, down 0.91% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.10 vs. $1.06 expected, and maintains robust profitability with 71.92% gross margin and 15.95% net margin. Recent FDA approval for Sarclisa's subcutaneous formulation provides growth catalyst.
SNY presents a compelling investment case with solid earnings performance and pipeline advancements, though regulatory scrutiny in Europe and patent expiration risks for key drug Dupixent in 2031 warrant monitoring. Analyst consensus leans positive with 44% buy ratings, supporting a constructive outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
